膳食胆固醇通过调节肠道菌群及其代谢物驱动脂肪肝相关肝癌
研究用高脂高胆固醇饮食喂养C57BL/6雄性小鼠14个月,观察到脂肪变性、脂肪性肝炎、纤维化直至肝细胞癌(HCC)的序贯进展,伴肠道菌群失调和代谢物改变;阿托伐他汀可完全预防HCC形成;高胆固醇血症患者粪便菌群变化与小鼠一致。
要点
- 高膳食胆固醇可驱动小鼠NAFLD相关HCC的序贯进展,并伴随胰岛素抵抗。
- 胆固醇诱导的HCC形成与肠道菌群失调相关,患者粪便菌群变化与小鼠一致。
- 阿托伐他汀可恢复胆固醇诱导的菌群失调并完全预防小鼠NAFLD-HCC发生。
核心结论
- 膳食胆固醇通过诱导肠道菌群及代谢物改变驱动小鼠NAFLD-HCC形成。
- 抑制胆固醇治疗和调控肠道菌群可能是预防NAFLD-HCC的有效策略。
研究设计与样本
- C57BL/6雄性同窝小鼠分别喂食高脂高胆固醇(HFHC)、高脂低胆固醇或正常饲料14个月。
- 对HFHC喂养小鼠给予降胆固醇药物阿托伐他汀。
- 无菌小鼠移植不同饮食小鼠粪便以确定胆固醇调节菌群的直接作用。
- 16S rRNA测序分析肠道菌群,液相色谱-质谱(LC-MS)代谢组分析血清代谢物。
- 检测59例高胆固醇血症患者和39例健康对照的粪便微生物组成。
主要发现
- 高膳食胆固醇导致小鼠脂肪变性、脂肪性肝炎、纤维化并最终发生HCC,伴胰岛素抵抗。
- 菌群组成沿脂肪变性、脂肪性肝炎和HCC阶段呈明显聚类。
- HFHC喂养小鼠中Mucispirillum、Desulfovibrio、Anaerotruncus和Desulfovibrionaceae顺序增加,而Bifidobacterium和Bacteroides耗竭,并在高胆固醇血症患者中得到印证。
- 膳食胆固醇诱导肠道细菌代谢物改变,包括牛磺胆酸增加和3-吲哚丙酸减少。
- 灌胃HFHC喂养小鼠粪便的无菌小鼠出现肝脏脂质蓄积、炎症和细胞增殖。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD)-associated hepatocellular carcinoma (HCC) is an increasing healthcare burden worldwide. We examined the role of dietary cholesterol in driving NAFLD-HCC through modulating gut microbiota and its metabolites. DESIGN: High-fat/high-cholesterol (HFHC), high-fat/low-cholesterol or normal chow diet was fed to C57BL/6 male littermates for 14 months. Cholesterol-lowering drug atorvastatin was administered to HFHC-fed mice. Germ-free mice were transplanted with stools from mice fed different diets to determine the direct role of cholesterol modulated-microbiota in NAFLD-HCC. Gut microbiota was analysed by 16S rRNA sequencing and serum metabolites by liquid chromatography-mass spectrometry (LC-MS) metabolomic analysis. Faecal microbial compositions were examined in 59 hypercholesterolemia patients and 39 healthy controls. RESULTS: High dietary cholesterol led to the sequential progression of steatosis, steatohepatitis, fibrosis and eventually HCC in mice, concomitant with insulin resistance. Cholesterol-induced NAFLD-HCC formation was associated with gut microbiota dysbiosis. The microbiota composition clustered distinctly along stages of steatosis, steatohepatitis and HCC. Mucispirillum, Desulfovibrio, Anaerotruncus and Desulfovibrionaceae increased sequentially; while Bifidobacterium and Bacteroides were depleted in HFHC-fed mice, which was corroborated in human hypercholesteremia patients. Dietary cholesterol induced gut bacterial metabolites alteration including increased taurocholic acid and decreased 3-indolepropionic acid. Germ-free mice gavaged with stools from mice fed HFHC manifested hepatic lipid accumulation, inflammation and cell proliferation. Moreover, atorvastatin restored cholesterol-induced gut microbiota dysbiosis and completely prevented NAFLD-HCC development. CONCLUSIONS: Dietary cholesterol drives NAFLD-HCC formation by inducing alteration of gut microbiota and metabolites in mice. Cholesterol inhibitory therapy and gut microbiota manipulation may be effective strategies for NAFLD-HCC prevention.
引用
- Zhang X, Coker OO, Chu ES, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut. 2020. PMID: 32694178. doi:10.1136/gutjnl-2019-319664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。